Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure

Sylvain Thepot, Simone Boehrer, MD, Thomas Prebet, Odile Beyne-Rauzy, E. Wattel, MD, Jacques Delaunay, MD, Emmanuel Raffoux, Francois Dreyfus, Stefan Wickenhauser, Mathilde Hunault-Berger, MD, PhD, Fatiha Chermat, Pierre Fenaux, MD, PhD, Lionel Ades, MD, PhD

Blood (2012) 120 (21): 1719.

https://doi.org/10.1182/blood.V120.21.1719.1719

Published: 2012

Journal Articles

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Marie Sebert, Elodie Lainey, PAscale Lepelley, Sylvain Thepot, Maximilien Tailler, Claude Gardin, MD, Guido Kroemer, MD, PhD, Simone Boehrer, Lionel Ades, Pierre Fenaux, MD, PhD

Blood (2011) 118 (21): 5028.

https://doi.org/10.1182/blood.V118.21.5028.5028

Published: 2011

Journal Articles

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Elodie Lainey, Marie Sebert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, MD, Guido Kroemer, MD, PhD, Pierre Fenaux, MD, PhD, Simone Boehrer, MD, PhD

Blood (2011) 118 (21): 2790.

https://doi.org/10.1182/blood.V118.21.2790.2790

Published: 2011

Journal Articles

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Blood (2011) 118 (21): 2564.

https://doi.org/10.1182/blood.V118.21.2564.2564

Published: 2011

Journal Articles

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Blood (2011) 117 (2): 403–411.

https://doi.org/10.1182/blood-2010-06-289280

Published: 2011

Journal Articles

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

Elodie Lainey, Marie Sebert, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Guido Kroemer, Pierre Fenaux, MD, PhD, Simone Boehrer

Blood (2010) 116 (21): 974.

https://doi.org/10.1182/blood.V116.21.974.974

Published: 2010

Journal Articles

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, Thomas Prebet, M.D., Ph.D., Aspasia Stamatoullas, Christian Recher, MD, PhD, Romain Guieze, Emmanuel Raffoux, Krimo Bouabdallah, Mathilde Hunault, Eric Wattel, Laure Stalnikiewicz, Andrea Toma, Herve Dombret, MD, Norbert Vey, Simone Boehrer, Claude Gardin, Pierre Fenaux, MD, PhD

Blood (2010) 116 (21): 508.

https://doi.org/10.1182/blood.V116.21.508.508

Published: 2010

Journal Articles

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Blood (2010) 116 (21): 3996.

https://doi.org/10.1182/blood.V116.21.3996.3996

Published: 2010

Journal Articles

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Marie Sebert, Elodie Lainey, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, Pierre Fenaux, MD, PhD, Guido Kroemer, Simone Boehrer

Blood (2010) 116 (21): 2163.

https://doi.org/10.1182/blood.V116.21.2163.2163

Published: 2010

Journal Articles

Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?

Sophie Cereja, Sabine Brechignac, Lionel Ades, Thorsten Braun, Simone Boehrer, Zehaira Hebibi, Rosa Sapena, Odile Beyne-Rauzy, Norbert Vey, Herve Dombret, Dominique Bordessoule, Francois Dreyfus, Pierre Fenaux, Claude Gardin

Blood (2010) 116 (21): 1868.

https://doi.org/10.1182/blood.V116.21.1868.1868

Published: 2010

Journal Articles

Hypomethylating Agents Correct Subcellular Localization of FOXO3a and (re)Establish Expression of Its Transcriptional Targets In AML and MDS- Cells

Sylvain Thepot, Elodie Lainey, Marie Sebert, Lionel Ades, Claude Gardin, Pierre Fenaux, MD, PhD, Guido Kroemer, Simone Boehrer

Blood (2010) 116 (21): 2173.

https://doi.org/10.1182/blood.V116.21.2173.2173

Published: 2010

Journal Articles

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Blood (2010) 116 (21): 1880.

https://doi.org/10.1182/blood.V116.21.1880.1880

Published: 2010

Journal Articles

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Simone Boehrer, MD, PhD, Lorenzo Galluzzi, phD, Lionel Ades, MD, Celine Fouassier, Claude Gardin, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2009) 114 (22): 3813.

https://doi.org/10.1182/blood.V114.22.3813.3813

Published: 2009

Journal Articles

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.

Lionel Ades, MD, Aspasia Stamatoullas, MD, Emmanuel Raffoux, MD, Thomas Prebet, MD, Pascal Lenain, MD, Romain Guieze, MD, Mathilde Hunault, MD, Eric Wattel, MD, PhD, Laurence Stalnikiewicz, MD, Krimo Bouabdallah, MD, Vincent Levy, MD, PhD, Norbert Vey, MD, PhD, Herve Dombret, MD, PhD, Simone Boehrer, MD, PhD, Claude Gardin, MD, Pierre Fenaux, MD, PhD

Blood (2009) 114 (22): 1049.

https://doi.org/10.1182/blood.V114.22.1049.1049

Published: 2009

Journal Articles

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

Lionel Adès, Simone Boehrer, Thomas Prebet, Odile Beyne-Rauzy, Laurence Legros, Christophe Ravoet, François Dreyfus, Aspasia Stamatoullas, Marie Pierre Chaury, Jacques Delaunay, Guy Laurent, Norbert Vey, Sara Burcheri, Rose-Marie Mbida, Natacha Hoarau, Claude Gardin, Pierre Fenaux

Blood (2009) 113 (17): 3947–3952.

https://doi.org/10.1182/blood-2008-08-175778

Published: 2009

Journal Articles

The Capacity of the Hypomethylating Agents Azacytidine and Decitabine to Induce Apoptosis and Cell Cycle Arrest Depends on the Activation of the DNA-Damage Response Pathway.

Simone Boehrer, Lionel Ades, Nicolas Tajeddine, Lorenzo Galluzzi, Stephane de Botton, Pierre Fenaux, Guido Kroemer

Blood (2008) 112 (11): 1655.

https://doi.org/10.1182/blood.V112.11.1655.1655

Published: 2008

Journal Articles

Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.

Simone Boehrer, Lionel Ades, Nicolas Tajeddine, Lorenzo Galluzzi, Wolf-Karsten Hofmann, Pierre Fenaux, Guido Kroemer

Blood (2008) 112 (11): 1656.

https://doi.org/10.1182/blood.V112.11.1656.1656

Published: 2008

Journal Articles

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

Simone Boehrer, Lionel Adès, Thorsten Braun, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, Génèviève Le Roux, Claude Gardin, Antoine Martin, Stéphane de Botton, Pierre Fenaux, Guido Kroemer

Blood (2008) 111 (4): 2170–2180.

https://doi.org/10.1182/blood-2007-07-100362

Published: 2008

Includes: Supplemental data

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, MD, Lionel Ades, MD, Thorsten Braun, MD, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, MD, Genevieve Le Roux, Claude Gardin, MD, Antoine Martin, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 399.

https://doi.org/10.1182/blood.V110.11.399.399

Published: 2007

Journal Articles

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Simone Boehrer, MD, Lionel Ades, MD, Lorenzo Galluzzi, Ken Olaussen, PhD, Thorsten Braun, MD, Jennifer Grosjean, PhD, Claire Fabre, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 2438.

https://doi.org/10.1182/blood.V110.11.2438.2438

Published: 2007

NARROW

A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure

Expression and Function of the P-Glycoprotein (P-gp) In Myelodysplastic Syndromes (MDS) Treated with Azacytidine (AZA)

Potentiation of Apoptosis in MDS/AML by Combination of Azacitidine and the EGFR-Tyrosine Kinase Inhibitor (TKI) erlotinib

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Erlotinib Increases Efficacy of 5-Azacitidine (AZA) by Inhibiting Drug Efflux Via ABC-Transporters

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) In AML and Higher Risk MDS with Del 5q. Results of a Phase I/II Study of the Groupe Francophone Des Myelodysplasies (GFM)

A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial

Erlotinib Inhibits ABC Transporters of AML Progenitors with Stem Cell Features and Increases Chemosensitivity to Current AML Drugs

Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?

Hypomethylating Agents Correct Subcellular Localization of FOXO3a and (re)Establish Expression of Its Transcriptional Targets In AML and MDS- Cells

Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/− Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study.

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

The Capacity of the Hypomethylating Agents Azacytidine and Decitabine to Induce Apoptosis and Cell Cycle Arrest Depends on the Activation of the DNA-Damage Response Pathway.

Selective Suppression of the DNA Damage Response in Acute Myeloid Leukemia Versus Myelodysplastic Syndrome.

Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Further Evidence That MDS and AML Cells Exhibit a Differential Capacity To Activate the DNA-Damage Response (DDR) Pathways.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only